Itepekimab
PDY16967
Phase 2 small_molecule active
Quick answer
Itepekimab for Chronic Obstructive Pulmonary Disease is a Phase 2 program (small_molecule) at Sanofi Pharma Bristol-Myers Squibb with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Sanofi Pharma Bristol-Myers Squibb
- Indication
- Chronic Obstructive Pulmonary Disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active